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Introduction
Chronic inflammatory bowel disease (IBD) is
increasing in industrialized countries, and this sug-
gests a role for exogenous factors, such as tobacco
and a high calorie diet, in the etiology of these dis-
eases(1,2,3). Several studies draw attention to the
abnormalities, due to exogenous insults, of the
saprophytic commensal micro flora with subse-
quent damage to tight mucosal joints with loss of
impermeability. This causes penetration of bacterial
antigens into the intercellular space with activation
of the mucosa-associated immune system.
Correlated with the loss of impermeability of the
mucosa, other studies have shown that the migra-
tion of macrophages and intestinal lymphocytes is
responsible for the onset of joint inflammation; this
has been evidenced due to the finding, in synovial
fluid, of antigens and bacterial genetic material,
often of gram-negative bacteria able to invade and
survive within the host cell, by use of polymerase
chain reaction(4). All this can be compatible with the
intestinal origin of these bacteria. Genetic alter-
ations of the histocompatibility complex B-27
(HLA-B27) and polymorphism of the receptor for
interleukin 23 (IL-23R) increase the risk and sus-
ceptibility of developing IBD when exposure to
exogenous environmental factors exist(5). In ulcera-
tive colitis (UC), the lesions are commonly located
in the rectum and extend to the entire colon in
absence of alternate areas of undamaged mucosa. In
UC, the mucosa appears hyperemic, and in severe
cases, bloody and ulcerated with pseudo-polyps.
Crohn’s disease (CD) can involve any part of the
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ABSTRACT
Clinical evidence suggests that arthritis is one of the complications of inflammatory bowel disease (IBD) of which the etio-
logical causes are still not completely understood. Among the possible explanations the most probable theory is poor regulation of
the intestinal immune system, which causes a cross-like immune reactivity against the resident micro flora. Arthritis in these sub-
jects involves different joints and is asymmetric, with greater involvement of the large joints of the lower limbs. Joints may also be
involved with the spinal forms of sacroileitis and ankylosing spondylitis. This clinical evidence explains the existence of
Lesniowski-Crohn’s disease, a variant of IBD in which patients have bone joint problems that may also be the primary manifesta-
tion of the disease.
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intestinal mucosa, with a typically segmental distri-
bution of the lesion, and there are unaffected areas
of mucosa along the gut. CD rarely affects the rec-
tum, with a possible presence of fistulas, abscesses
and/or anal stenosis. Peripheral arthritis is common
in CD and worsens with exacerbations of the
intestinal manifestations, often involving multiple
upper and lower large joints in asymmetric, migra-
tory ways(6).
The histological-pathological framework in
arthritis secondary to chronic inflammatory bowel
disease appears similar to that of rheumatoid arthri-
tis due to the presence of synovial hypertrophy,
lymphoid infiltrate and synovial pannus develop-
ment. The characteristics that identify arthritis as a
complication of inflammatory bowel diseases are
the presence of cartilage erosions at the center of
the joint surface, quite different from erosion type,
tail of mouse and lesion without fish scale present
only on synovial areas, distinctive of rheumatoid
arthritis. For this reason the best approach for the
physician is a multi-disciplinary one, in both diag-
nostics and therapy.
Materials and methods
Collected data were obtained from studies
conducted at the University of Palermo between
2004 and 2011, by simple random sampling. In the
classification of patient status, the medical history
was considered. Some patients had already been
studied for inflammatory bowel disease (IBD), and
in these cases our attention was directed towards
understanding whether the arthritic symptoms were
primary manifestations, or a complication of IBD.
In acute involvement joints appear swollen, due to
the presence of effusion, redness, and with loss of
normal joint profile; pain was present both at rest
and during passive movement; altered range of
motion with a moderate degree of functional
impairment may also be found. In some patients
induction of loco-regional analgesia was necessary
in order to perform the specific semiological test of
involved joints.
The diagnostic procedure is continued with the
evaluation of inflammation bio-humoral values
such as the leukocyte formula, erythrocyte sedi-
mentation rate, C-reactive protein (CRP), and
rheumatoid factor. X-ray investigations were per-
formed to properly stage the degeneration of carti-
lage in the involved joints. Endoscopic examina-
tions with biopsy and histological examination
were performed at the outpatient endoscopy clinic
of the Department of Surgery, Faculty of Medicine,
University of Palermo. 
Results
Altogether, 128 patients were studied: 82
(64.06%) suffered from ulcerative colitis (UC)
(mean age 55.5 years, range 19-75 years), and 60
from CD, with only 45 (35.16%) (mean age 54.1
years, range 17-75 years) having a firm diagnosis,
while the remaining 15 patients had an unclear clin-
ical picture and therefore underwent further investi-
gation. One patient with CD was excluded for poor
compliance (Table 1). A breakdown of joint
involvement exhibits the following topography:
arthritis of the hip was present in 12 patients (50%),
while arthritis of the shoulder was present in nine
patients (37.5%); 22 patients (91.6%) had peripher-
al arthritic involvement (10 patients had knee
involvement, and 8 patients ankle involvement);
among the patients with bone joint complications of
inflammatory bowel disease, six (25%) were affect-
ed by spondylitis, and four (16.67%) by sacroili-
itis(7).
Our study also aimed to determine whether
there is a significant relationship between rectal
ulcerative colitis and arthritis, and/or CD and arthri-
tis. To this end, a simple random sample of 128
patients, including 82 with rectal ulcerative colitis,
was selected. In this group, 68 patients also had
arthritis. With the initial chi-square statistic test, we
found a value that amounted to 46.275, which was
significant for α = 0.05 (46.275 › 3.84) and a p-
value of ‹ 0.001; these results prove that there is a
significant relationship between rectal ulcerative
colitis and arthritis. Although the chi-square test
allowed us to determine the association between the
OVERVIEW TOTAL PATIENTS
ENROLLED 143
WITH ULCERATIVE COLITIS 82
WITH CROHN’S DISEASE 46*
EXCLUDED FOR UNCERTAIN DIAGNOSIS 15
*EXCLUDED FOR POOR COMPLIANCE 1
Table 1: Patients enrolled and their distribution by dia-
gnosis.
two variables, it does not provide any means to
measure the strength of this association.
Therefore, we proceeded by calculating the
Cramer’s V value, normalized within the range of
0.1; with a result of 0.60, this shows the presence of
a fair degree of dependence. Finally, the odds ratio
was calculated: the sample data had a value of
17.48, showing that the risk of also having arthritis
in the group of patients with UC is 17.48 times
higher compared to the unaffected group. It also
provides the confidence interval limits (95%) for
the population; the odds ratio was between 7.06 and
43.23. To test our second research hypothesis, and
determine whether there is a significant relationship
between arthritis and CD, we proceeded similarly:
of the 78 patients with arthritis, 45 also had CD; the
statistical test had a value of 9.436 which is signifi-
cant for α = 0.05, and it could therefore be conclud-
ed that there is a significant association between the
two variables. To quantify the strength of the rela-
tionship between these variables (arthritis and CD),
we calculated Cramer’s V value, which was equal
to 0.27, showing a modest association. Following
the calculation of the p-value, which was between
0.01 and 0.001, an odds ratio of 3.18 was found.
These data show that the risk of CD is 3.18 times
higher in patients with arthritis than in the unaffect-
ed group. Again, we calculated the odds ratio of the
population (95% confidence interval), which was
found to be between 1.49 and 6.71.
In synthesis, with reference to the first
research hypothesis, it can be concluded that
patients with rectal ulcerative colitis are more likely
to have arthritis than those who do not have this
type of ulcerative colitis. With reference to the sec-
ond hypothesis, it can be concluded that patients
with arthritis have a greater chance of developing
CD compared to patients without arthritis.
Our results are compared to the findings from
the international literature in Figure 1 and Figure 2.
Discussion
The prevalence of IBD, including 64.6% of
patients with ulcerative colitis and 35.9% with CD,
found during our study, is completely consistent
with previous Italian data by Tragnone et al.(8), but
similar to the prevalence rates found in Europe
according to a study by Shivananda et al.(9). From
our analysis, it can be noted that the anatomical
sites involved in the arthritic process include main-
ly the large joints of the lower limbs; the only dif-
ference is with the previous study by Yukel et al.: in
our study the primary involvement of hip, whilst in
the former, the knee and ankle were most affected.
The management of patients with IBD arthritis
is very complex due to the need for multidiscipli-
nary clinical intervention that should be performed
to respond to requirements of the patients estab-
lished during the medical examination. From the
moment the patient has received the communica-
tion of a definitive diagnosis of inflammatory and
chronic disease there is a period of considerable
psychological stress. In orthopedic units the main
request of the patients was the need to be able to
live without pain and with improved joint function.
Satisfactory results were obtained with the use
of intra-articular viscosupplementation therapy with
high molecular weight hyaluronic acid sodium salt:
1.5% at dosages of 30 mg (for the major joints),
administered every week for 3-4 weeks(10). In syner-
gy with infiltrative therapy, repeated physiotherapy
has improved the elasticity of capsular and pericap-
sular soft tissue increasing joint range of movement
(ROM). In cases in which the cartilage degenera-
tion was severe, with initial signs of ankylosis,
prosthetic surgery was recommended to the patient.
In our opinion anti-inflammatory therapies with
fans are absolutely contraindicated, due to their
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Fig. 1: Relative prevalence data of inflammatory bowel disease
in Palermo, Italy and Europe. The trend observed during our
study is nearly identical to that of the European context.
Fig. 2: Anatomical distribution of joint involvement during the
course of inflammatory bowel disease. The prevailing
European trend is the involvement of the knee and ankle, while
our study in Palermo found a greater prevalence of the hip. In
both cases, the lower limbs are the most involved.
injurious effect on gastric mucosa, already eroded
by the pathogenic mechanism of IBD(11,12). Most
patients with IBD had therapy with 5-amino sali-
cylic acid (5-ASA) in combination with probiotics.
The 5-ASA performs an anti-inflammatory action
that is expressed at the level of the epithelial cells
of the colon. The drug is administered as a pro-drug
which requires the action of specific enzymes pro-
duced by the commensal microflora to be activated.
This is a reason for therapeutic association of
5-ASA with probiotics, which, by increasing the
concentration, at the level of the mucosa, of the
azoreductase enzyme, promotes the increase in con-
centration of 5-ASA activated; thus resulting in a
better therapeutic response: levels of complications
from overdose declined significantly. Clinical trials
at the University of Palermo evaluated the response
to treatment with 5-ASA plus probiotics(13), measur-
ing the levels of heat shock proteins (HSP) in frus-
tules of mucosa taken from the colon. Then results
were compared with the levels of HSP found in
frustules of mucosa of patients who received only
5-ASA. The studies were conducted at the Institute
of Normal Human Anatomy of the Polyclinic
Hospital, Palermo; the HSPs evaluated were the
HSP 60, HSP 10, HSP 70, HSP 90. Laboratory data
showed that in patients who performed the com-
bined therapy (5-ASA plus probiotic) levels of HSP
60, HSP 10 were reduced significantly both at
epithelial and at the sub-epithelial level after six
months of treatment. HSP 70 is significantly
reduced only in the epithelial layer and HSP 90 was
reduced exclusively only at the sub-epithelium
layer and only in patients receiving 5-ASA plus
probiotics(14,15,16). The main results that emerge from
our analyses are:
• the prevalence of IBD is stable in the
European context.
• the joint most affected in our area (Palermo)
is the hip, while in the European context, knee and
ankle are the most affected joints. 
• biological therapies with probiotics and ac.
hyaluronic acid are essential adjuvants for medical
treatment of the patient with IBD.
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